ARID1A and cholangiocarcinoma: Studies evaluating AKT inhibitors (MK-2206) in ARID1A-deficient cholangiocarcinoma cell lines revealed increased sensitivity to the drug, suggesting that targeting the PI3K/AKT pathway could improve therapeutic outcomes in these tumors [54].